



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#8  
YC  
42903  
RECEIVED  
APR 17 2003  
TECH CENTER 1600/2900

In re Application of :

Ralph LIPP et al.

Group Art Unit 1615

Serial No.: 10/022,834

Examiner: Young

Filed: December 20, 2001

For: TRANSDERMAL SYSTEM THAT CONTAINS A NEW HIGHLY POTENT  
GESTAGEN

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Assistant Commissioner for Patents  
Washington, D. C. 20231

Sir:

CITED MATERIALS

Applicant(s) wish to disclose the following information, listed in the attached form PTO-1449.

- ☐ Copies of materials listed but not attached were cited in parent application Serial No. \_\_\_\_\_.
- ☐ Copies of materials listed but not attached were cited in an International Search Report dated \_\_\_\_\_; receipt of any International Search Report and copies of references were confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed \_\_\_\_\_.
- ☒ Copies of materials listed and attached were cited in a communication from a foreign patent office in a counterpart foreign application.
- ☐ Also included are the pending U.S. applications listed below, copies of which are attached:

FEES

- ☐ No fee is required for this Information Disclosure Statement because:
- ☐ This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
- ☐ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;

☐ This Information Disclosure Statement is being filed before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.

☒ A check is attached: This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).

☐ A check is attached: This Information Disclosure Statement is being filed after the mailing date of a notice of allowance under § 1.311 but before the payment of the issue fee and is accompanied by the fee set forth in § 1.17(p) and a certification below.

#### **CERTIFICATION**


☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

#### **DEPOSIT ACCOUNT**

If appropriate, attached is a check in the amount of \$ 180.00. However, the Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

  
Jennifer Branigan  
Registration No.40,921  
Patent Agent

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Date: 9 April 2003  
JJB:I:IDS\IDS with SR.doc

I hereby certify that this correspondence is being deposited with the U.S. Postal Services as First Class Mail in an envelope addressed to:  
Assistant Commissioner For Patents,  
Washington, D.C. 20251 on: 9 April 03  
Name: Jennifer Branigan  
Signature: [Handwritten Signature]  
Date: 9 April 03